Compare INVZ & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | INO |
|---|---|---|
| Founded | 2016 | 1979 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.5M | 133.4M |
| IPO Year | 2020 | 1999 |
| Metric | INVZ | INO |
|---|---|---|
| Price | $0.30 | $1.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.68 | ★ $6.75 |
| AVG Volume (30 Days) | 2.4M | ★ 3.7M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | $29.61 | $20,156.19 |
| Revenue Next Year | $53.57 | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $0.31 | $0.56 |
| 52 Week High | $2.54 | $2.72 |
| Indicator | INVZ | INO |
|---|---|---|
| Relative Strength Index (RSI) | 31.43 | 48.24 |
| Support Level | N/A | $1.03 |
| Resistance Level | $0.37 | $1.24 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 5.49 | 6.90 |
Innoviz Technologies Ltd is a provider of LiDAR technology, serving as a Tier 1 supplier to the world's automotive manufacturers. Its LiDAR and perception software "see" further than a human driver and reduce the possibility of error, meeting the automotive industry's strictest expectations for performance and safety. Its sensors are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing in harsh weather conditions. Operating across the U.S., Europe, and Asia. Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, and others. InnovizSMART is an off-the-shelf solution for security, defense, and homeland security, intelligent traffic management, mobility, robotics, and aerial applications.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.